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The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a measure of axial spondyloarthritis 
(axSpA) disease activity with validated cut-offs endorsed by the Assessment of Spondyloarthritis 
international Society (ASAS) and Outcome Measures in Rheumatology (OMERACT).1,2 In 2016 
update of the ASAS-EULAR management recommendations for axSpA it is recommended that 
biological disease-modifying antirheumatic drugs (bDMARDs) should be considered in patients with 
persistently high disease activity despite conventional treatments, and that the preferred measure 
to define active disease should be the ASDAS (ASDAS of at least 2.1, i.e. high disease activity).3 The 
2017 update of treat-to-target recommendations in axial and peripheral SpA, recommends that the 
treatment target should be inactive disease/clinical remission and that low/minimal disease activity 
may be an alternative treatment target. The same recommendations state that the preferred 
measure to define the target in axSpA is the ASDAS.4 
ASDAS cut-offs for disease activity states are 1.3, separating “inactive disease” from “moderate 
disease activity”, 2.1, separating “moderate disease activity” from “high disease activity”, and 3.5, 
separating “high disease activity” from “very high disease activity”. While inactive disease equates 
to a remission-like state, there is no low/minimal disease equivalent in the above nomenclature of 
ASDAS cut-offs. At the 2018 ASAS annual meeting in Lisbon, Portugal, ASAS members discussed the 
proposal of changing the nomenclature of ASDAS cut-offs in order to fill this gap. 
Arguments to change the designation of “moderate disease activity” to “low disease activity” were 
presented. The compelling argument is the fact that the majority of patients in this ASDAS category 
have indeed mild disease activity, an observation that is in line with the external constructs that 
were used to derive the ASDAS cut-off of 2.1: patient and physician global assessments <3, using 
the 90% specificity criterion to determine the optimal cut-off.1,5 Furthermore, recent publications 
have shown that the majority of patients with ASDAS values in the “moderate disease activity” 
category consider themselves as being in a patient-acceptable symptom state (PASS), which can be 
defined as the maximum level of symptoms with which patients consider themselves to be well. 
Godfrin-Valnet et al6 found that agreement between ASDAS-C-reactive protein (CRP) and ASDAS-
erythrocyte sedimentation rate (ESR) was good and that values of ≤2.3 for each were associated 
with the PASS. A previous study by Rodriguez-Lozano et al7 suggested cutoff values between 2.5 and 
3.0 for ASDAS-CRP and cutoff values between 2.8 and 3.5 for ASDAS-ESR (PASS as external 
construct), depending on the method used to determine the cutoff value. A more recent study by 
Sellas et al8 suggested that the ASDAS cut-off of 2.04 was associated with patient-PASS while the 
ASDAS cut-off of 2.44 was associated with physician-PASS.  
Following an open discussion among ASAS members about the topic, the proposed nomenclature 
change from ASDAS “moderate disease activity” to ASDAS “low disease activity” was voted and 
approved by ASAS members (Figure 1). Other possibilities that were considered but rejected by 
ASAS members were the use of the wording “low/moderate disease activity”, “mild disease activity” 
and “moderate/high disease activity” (the later proposed to replace “high disease activity” state). 
In conclusion, the nomenclature of ASDAS disease activity states was updated by ASAS. The 
“moderate disease activity” state is replaced by “low disease activity” state, better reflecting the 
opinion of patients and physicians about what ASDAS values ≥1.3 and <2.1 represent. This change 
will improve the interpretability of ASDAS scores and will facilitate the implementation of treat-to-
target strategies in axSpA. 
 
 
Figure 1. 2018 update of the nomenclature for ASDAS disease activity states. ASDAS, Ankylosing 
Spondylitis Disease Activity Score. 
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